Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

5.15USD
10:04am EST
Change (% chg)

$-0.05 (-0.96%)
Prev Close
$5.20
Open
$5.23
Day's High
$5.27
Day's Low
$5.15
Volume
32,834
Avg. Vol
175,692
52-wk High
$15.01
52-wk Low
$4.10

Select another date:

Mon, Nov 20 2017

Ex-Insys employee's lawyer does not need to be disqualified from bribe case: judge

A federal magistrate judge has ruled that a lawyer's previous representations of other Insys Therapeutics Inc employees does not warrant his disqualification from defending a former Insys regional sales director against charges she engaged in a scheme to bribe doctors to prescribe an opioid.

Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

UPDATE 2-Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

Billionaire founder of Insys to plead not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of Insys Therapeutics Inc was expected to appear in federal court in Boston on Thursday to plead not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug.

Insys founder fights electronic monitoring ahead of bribery trial

Lawyers for Insys Therapeutics Inc's billionaire founder sought on Monday to loosen his bail conditions while he awaits trial on charges that he engaged in a scheme to bribe doctors to prescribe an opioid drug, attacking the case against him as "thin."

Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

UPDATE 2-Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON, Nov 2 Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

BRIEF-Insys Therapeutics reports Q3 loss per share of $2.30

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Insys Therapeutics posts net loss in third quarter

Nov 2 Insys Therapeutics on Thursday reported a net loss for the third quarter, compared to a year-ago profit, amid an investigation of the U.S. drugmaker's founder on charges of bribery.

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

Select another date: